Clinical Trial Update: POTENT - Tepotinib in Combination With Pembrolizumab in NSCLC [Phase 1]

View source ↗

Summary

This document reports an ongoing Phase 1 trial evaluating the combination of tepotinib and pembrolizumab for non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• Tepotinib (tepotinib)

Snippet

Sponsor: Institute of Cancer Research, United Kingdom | Conditions: Advanced Cancer, Non Small Cell Lung Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING